Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

Cleveland Clinic Heart Failure Summit 2025

Introduction

The Cleveland Clinic Heart Failure Summit: Expanding the Frontiers of Contemporary Team Management 2025 is an advanced cardiovascular education program focused on modern multidisciplinary management of heart failure across the continuum of care. Presented by Cleveland Clinic, the course delivers practical and evidence-based updates in pharmacologic therapy, device management, electrophysiology, cardiomyopathy care, and advanced heart failure interventions.

The curriculum emphasizes contemporary team-based cardiovascular care while integrating:

• Guideline-directed heart failure therapy
• HFrEF and HFpEF management
• Cardiac amyloidosis
• Hypertrophic cardiomyopathy
• Electrophysiology in heart failure
• Sudden cardiac death prevention
• Mechanical and surgical therapies
• Novel pharmacologic interventions
• Advanced cardiovascular therapeutics
• Multidisciplinary heart failure management

into a clinically practical educational experience designed to improve outcomes for complex heart failure patients.

---

Course Overview

📚 Program: Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025

🏛️ Presented by Cleveland Clinic

🎥 Included Content

• 7 video lectures
• 38 PDF presentations

💾 Course Size: 2.21 GB

🎓 Educational Format

• Expert-led cardiovascular lectures
• Guideline-focused education
• Advanced heart failure reviews
• Case-based clinical discussions
• Multidisciplinary management strategies

The course is designed to provide practical updates in contemporary heart failure care and advanced cardiovascular management.

---

Educational Focus

The program focuses on:

• Advanced heart failure management
• HFrEF and HFpEF therapies
• Novel cardiovascular pharmacology
• Device-based heart failure interventions
• Cardiac electrophysiology
• Cardiac amyloidosis
• Hypertrophic cardiomyopathy
• Sudden cardiac death prevention
• Multidisciplinary cardiovascular care
• Team-based heart failure management

The curriculum integrates evidence-based medicine with clinically practical therapeutic strategies.

---

Learning Objectives

After completing this activity, learners strengthen their ability to:

• Optimize use of current and novel heart failure therapies for reduced ejection fraction
• Differentiate reduced versus preserved ejection fraction heart failure phenotypes
• Apply advanced medical devices and surgical therapies in heart failure care
• Discuss emerging therapies for HFmrEF and HFpEF
• Employ contemporary management strategies for cardiac amyloidosis and hypertrophic cardiomyopathy
• Identify electrophysiologic interventions for atrial arrhythmias and sudden cardiac death prevention
• Improve multidisciplinary coordination in advanced cardiovascular care

The educational material emphasizes modern guideline-directed management and practical clinical implementation.

---

Heart Failure Pharmacologic Management

A major educational component focuses on optimization of medical therapy in heart failure.

Covered Areas

• Guideline-directed medical therapy (GDMT)
• Novel heart failure pharmacology
• HFrEF treatment optimization
• HFmrEF management
• HFpEF therapies
• Advanced pharmacologic strategies
• Contemporary evidence-based drug therapy

The curriculum reviews current and emerging therapies designed to improve outcomes in chronic heart failure.

---

Heart Failure Phenotypes & Clinical Profiles

Dedicated sessions review the clinical spectrum of heart failure syndromes.

Topics Include

• Reduced ejection fraction heart failure
• Preserved ejection fraction heart failure
• Midrange ejection fraction heart failure
• Clinical phenotyping strategies
• Diagnostic differentiation
• Hemodynamic and structural considerations

Participants strengthen practical understanding of diverse heart failure presentations and treatment approaches.

---

Device Therapy & Surgical Interventions

The course reviews modern procedural and surgical options in advanced heart failure care.

Educational Topics

• Implantable cardiac devices
• Cardiac resynchronization therapy
• Defibrillator therapy
• Surgical heart failure interventions
• Mechanical circulatory support concepts
• Device-based management strategies

The sessions emphasize practical integration of procedural therapies into comprehensive cardiovascular care.

---

Cardiac Amyloidosis & Hypertrophic Cardiomyopathy

Specialized lectures focus on infiltrative and structural cardiomyopathies.

Covered Areas

• Cardiac amyloidosis recognition and management
• Hypertrophic cardiomyopathy therapeutics
• Advanced cardiomyopathy evaluation
• Imaging and diagnostic strategies
• Disease-specific management principles

The curriculum highlights emerging therapies and modern approaches to complex myocardial disease.

---

Electrophysiology & Arrhythmia Management

A major educational focus involves rhythm management in heart failure patients.

Topics Include

• Sudden cardiac death prevention
• Atrial arrhythmia management
• Electrophysiologic interventions
• Rhythm-control strategies
• Device therapy integration
• Arrhythmia risk reduction

Participants gain practical understanding of electrophysiologic approaches in advanced cardiovascular disease.

---

Team-Based Heart Failure Care

The course strongly emphasizes multidisciplinary cardiovascular management.

Educational Themes

• Integrated heart failure programs
• Collaborative patient management
• Multidisciplinary cardiovascular teams
• Coordinated chronic disease care
• Comprehensive patient-centered strategies

The program highlights the importance of collaborative care models in improving long-term outcomes.

---

Educational Experience

The summit combines:

• Expert-led cardiovascular lectures
• Evidence-based therapeutic reviews
• Advanced heart failure updates
• Practical management strategies
• Case-based discussions
• Multidisciplinary cardiovascular education

The educational structure emphasizes clinically applicable learning for contemporary heart failure practice.

---

Why This Course Stands Out

Contemporary Heart Failure Focus

Provides advanced review of modern pharmacologic and procedural heart failure therapies.

Multidisciplinary Team Management

Highlights integrated cardiovascular care models and collaborative management strategies.

Advanced Cardiomyopathy Education

Includes specialized coverage of cardiac amyloidosis and hypertrophic cardiomyopathy.

Strong Electrophysiology Integration

Reviews arrhythmia management and sudden cardiac death prevention in heart failure populations.

Practical Clinical Application

Emphasizes evidence-based therapies directly applicable to daily cardiovascular practice.

---

Clinical Value

The Cleveland Clinic Heart Failure Summit Expanding the Frontiers of Contemporary Team Management 2025 delivers advanced cardiovascular education through integrated coverage of:

• HFrEF management
• HFpEF and HFmrEF therapies
• Novel heart failure pharmacology
• Device-based interventions
• Cardiac electrophysiology
• Sudden cardiac death prevention
• Cardiac amyloidosis
• Hypertrophic cardiomyopathy
• Surgical heart failure therapies
• Multidisciplinary cardiovascular management
• Advanced heart failure care
• Evidence-based therapeutic strategies

The combination of expert-led instruction, multidisciplinary clinical education, and contemporary therapeutic updates makes this summit highly valuable for clinicians managing complex heart failure patients.

 

Topics:

• Agenda.pdf
  June 6 Advanced evaluation of the breathless patient.pdf
  June 6 AF ablation and the pulsed field era.pdf
  June 6 Arrhythmogenic cardiomyopathies and genetic testing.pdf
  June 6 Breakthroughs in obesity-related HFpEF.pdf
  June 6 Cardiac contractility modulation.pdf
  June 6 Current and emerging device-based therapies for HFpEF.pdf
  June 6 Educating and engaging the patient of tomorrow.pdf
  June 6 GDMT optimization across the inpatient-outpatient domain.pdf
  June 6 Harnessing tech for GDMT optimization and readmission reduction.pdf
  June 6 Harnessing the heart team for GDMT equity.pdf
  June 6 HF STATS The changing face of heart failure.pdf
  June 6 Lessons learnt for diverse HF trial recruitment.pdf
  June 6 New insights into HFpEF mechanisms.pdf
  June 6 Novel therapies for cardiomyopathies.pdf
  June 6 Remote monitoring in the “AI era”- Leveraging new devices and algorithms.pdf
  June 6 Remote monitoring the “old school” way- Weights, vitals and symptoms.pdf
  June 6 Session 1 – Updates in HF Epidemiology and Population Health.mp4
  June 6 Session 2 – HFrEF and EP Innovations.mp4
  June 6 Session 3 – HFpEF and Pulmonary Hypertension.mp4
  June 6 Session 4A – Meet the Clinical Trialists (Concurrent Session).mp4
  June 6 The future of remote HF and EP monitoring.pdf
  June 6 The LAA and controversies in anticoagulation.pdf
  June 6 The next frontier- earlier diagnosis and treatment of HF.pdf
  June 6 The next generation HFrEF therapies.pdf
  June 6 Trials and tribulations in valvular interventions.pdf
  June 6 Ventricular tachycardia in patients with HFrEF.pdf
  June 6 What’s new in pulmonary hypertension.pdf
  June 7 A positive PET scan- What comes next.pdf
  June 7 Collapse to comeback- Improving outcomes after cardiac arrest.pdf
  June 7 DanGer ahead- Seeking an evidence base for shock management.pdf
  June 7 Evolutions in organ preservation and transportation.pdf
  June 7 Fixing the flow- Revascularization for the high-risk patient.pdf
  June 7 Getting shock right- Managing the right ventricle.pdf
  June 7 HCM in the era of myosin inhibition.pdf
  June 7 LVADs in a Transplant World.pdf
  June 7 Managing MCS at a non-transplant center.pdf
  June 7 Managing TTR cardiac amyloidosis in 2025.pdf
  June 7 Multidisciplinary cardiac care during pregnancy.pdf
  June 7 Post-heart transplant outcomes and management innovations.pdf
  June 7 Session 1 – Cardiomyopathies (amyloid, HCM, Sarcoid) and HFrEF.mp4
  June 7 Session 2 – MCS and TX.mp4
  June 7 Session 3 – Cardiogenic shock and critical care.mp4
  June 7 The next generation of LVADs and trials.pdf
  June 7 Transplant and VAD options in congenital conditions.pdf